when

Latest
Archive

by source

All Sources
Sources Page

department

Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access

therapeutic area

Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease

location & type

Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →

by stage

Marketed
Phase 3
Phase 2
Phase 1
Preclinical

browse

Most catalysts
Recently active
All drugs →
Companies
Patent cliff

what

Trial readouts
PDUFA dates
Approvals
Earnings

when

Upcoming
Month grid
Recently passed

Sign In Subscribe

pharmadog

fetch the data · sniff the signal

Discover

Jobs
News
Drugs
Calendar
Companies

Hubs

Topics
Patent cliff
Publications
Readouts

Tools

Compare
Search
Bookmarks

Trust

About
Sources
Contact

Legal

Privacy
Terms
Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

home
jobs
news
search

NOVO · news · pharmadog

← back to NOVO

News mentioning NOVO

476 stories

Sep 21, 26Novo’s plan to hit $23B in revenue by 2035 leaves investors wantingbiospace

Sep 21, 26STAT+: Pharmalittle: We’re reading about Novo plans to expand its pipeline, early Alkermes ADHD data, and morestat

Sep 21, 26Novo buys three early-stage obesity assets from Kallyope as investor pressure mountsbiospace

Sep 21, 26Novo aims to diversify with new pipeline assets and bolt-on dealsendpoints

Sep 21, 26Novo struggles to appease restive investors with consumer plans, blockbuster ambitionsfiercebiotech

Sep 21, 26STAT+: With new strategy, Novo outlines plans for obesity, direct-to-consumer workstat

Sep 19, 26Another Novartis failure; Novo drops the ‘Nordisk’; and moreendpoints

Sep 18, 26CHMP backs Novo’s hemophilia A drug and seven other medicinesendpoints

Sep 18, 26STAT+: Up and down the ladder: The latest comings and goingsstat

Sep 18, 26STAT+: Pharmalittle: We’re reading about licensing deals with China, making drugs in space, and morestat

Sep 18, 26Refreshed Novo corrals 3 new early-stage obesity drugs from Kallyopefiercebiotech

Sep 17, 26Definium’s new psychedelics data, and a reprieve for international scientistsstat

Sep 17, 26Novo partners with Orbis, deepening investment in oral peptide drugsbiopharma dive

Sep 17, 26A Parkinson's biotech debut, fundraising campaign and licensing dealendpoints

Sep 17, 26Novo notches up to $1.4B pact with Orbis to develop oral macrocycle cardiometabolic drugsbiospace

Sep 17, 26Lilly-backed Orbis does up to $1.4B macrocycle deal with Novoendpoints

Sep 17, 26Trending: Top biopharma disciplines with jobs live nowbiospace

Sep 17, 26Biopharma hiring hotspots: States, disciplines where demand is highestbiospace

Sep 17, 26Recon: Senate hearing set for FDA nominee; Novo partners with Anthropic for AI drug developmentraps

Sep 16, 26'Still a bull': Novo's CEO on honoring heritage and planning for the future amid corporate rebrandfiercebiotech

Sep 16, 26Novo looks to Anthropic’s AI models to ‘supercharge’ drug developmentbiopharma dive

Sep 16, 26Novo signs Anthropic deal to test Claude Science in R&Dendpoints

Sep 16, 26STAT+: Pharmalittle: We’re reading about faster FDA approvals, access to experimental drugs in Montana, and morestat

Sep 16, 26FDA hears input on psychedelics, PDUFA, lung cancer’s next-gen therapies boost survivalbiospace

Sep 16, 26Novo explores macrocycles’ potential in $1.4B cardiometabolic pact with Danish biotechfiercebiotech

Sep 15, 26FDA clears first generic radioligand drug; Sionna turns to layoffsbiopharma dive

Sep 15, 26Rocket's Danon plans; Novo leaves Ascendis; Lilly's latest dealendpoints

Sep 15, 26STAT+: Pharmalittle: We’re reading about a GSK deal for a drug from China, job losses in the U.S., and morestat

Sep 15, 26STAT+: Vera kidney drug Trutakna shows strong final results in Phase 3 trialstat

Sep 15, 26Novo walks away from $285M pact to develop monthly GLP-1 obesity drug with Ascendisfiercebiotech

← prevpage 6 of 16next →